#1 Clinical Trials Search in Europe

Etrumadenant

Etrumadenant, also known as AB928, is an innovative drug currently being studied in various clinical trials for its potential in treating different types of cancer. This article will provide an overview of the ongoing research on etrumadenant, its mechanisms of action, and its potential benefits in combination with other cancer treatments.

Table of Contents

What is Etrumadenant?

Etrumadenant is a new drug being developed for cancer treatment. It is also known by other names such as AB928 and Etruma[1]. This medication is currently undergoing clinical trials to evaluate its safety and effectiveness in treating various types of cancer.

How Does Etrumadenant Work?

Etrumadenant belongs to a class of drugs called A2aR and A2bR antagonists[2]. These are molecules that block specific receptors in the body called A2a and A2b receptors. By blocking these receptors, Etrumadenant aims to boost the immune system’s ability to fight cancer cells. This approach is part of a broader category of cancer treatments known as immunotherapy, which harnesses the power of the body’s own immune system to combat cancer.

What Conditions Does Etrumadenant Treat?

Etrumadenant is being studied for the treatment of several types of cancer, including:

  • Urothelial Carcinoma: A type of bladder cancer[3]
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer[4]
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): An advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy[5]
  • Colorectal Cancer: Cancer that starts in the colon or rectum[6]
  • Gastroesophageal Cancer: Cancer that affects the stomach and esophagus[6]
  • Dedifferentiated Liposarcoma: A rare type of cancer that develops in fat tissue[7]

Current Clinical Trials

Etrumadenant is currently being evaluated in several clinical trials. These trials are designed to test the drug’s safety, effectiveness, and how it interacts with other medications. Some key studies include:

  • A Phase 2 study for patients with urothelial carcinoma who have previously received immunotherapy[3]
  • A study investigating how the body absorbs, processes, and eliminates Etrumadenant[8]
  • A trial examining how Etrumadenant interacts with other drugs, such as itraconazole (an antifungal medication)[2]
  • Studies evaluating Etrumadenant in combination with other cancer treatments for various types of cancer[4][5][6][7]

Combination Therapies

Researchers are particularly interested in how Etrumadenant works when combined with other cancer treatments. Some notable combinations being studied include:

  • Etrumadenant with Zimberelimab (AB122): Zimberelimab is another immunotherapy drug that targets a protein called PD-1[3]
  • Etrumadenant with Domvanalimab (AB154) and Zimberelimab: This triple combination is being tested in lung cancer patients[4]
  • Etrumadenant with chemotherapy drugs like mFOLFOX (a combination of several chemotherapy medications)[6]

These combinations aim to enhance the overall effectiveness of cancer treatment by attacking cancer cells through multiple mechanisms.

How is Etrumadenant Administered?

Etrumadenant is typically given as an oral medication, meaning it’s taken by mouth. In most clinical trials, it’s administered daily[3][6]. However, the exact dosage and schedule may vary depending on the specific study and the patient’s condition.

Potential Side Effects

As Etrumadenant is still in clinical trials, its full range of side effects is not yet known. Researchers are closely monitoring patients for any adverse reactions. Common side effects of cancer immunotherapies can include fatigue, skin reactions, and gastrointestinal issues. However, it’s important to note that each person may react differently to the medication[3][4][5].

Future Prospects

Etrumadenant shows promise in the field of cancer immunotherapy. If the ongoing clinical trials demonstrate its safety and effectiveness, it could become an important new option for cancer treatment, particularly for patients who have not responded well to other therapies. However, it’s important to remember that drug development is a long and complex process, and more research is needed before Etrumadenant can be approved for widespread use[3][4][5][6][7].

Aspect Details
Drug Name Etrumadenant (AB928)
Mechanism of Action A2aR and A2bR antagonist
Administration Oral, daily dosing
Cancer Types Studied Non-small cell lung cancer, gastroesophageal cancer, colorectal cancer, prostate cancer, urothelial carcinoma
Common Combinations Zimberelimab (AB122), domvanalimab (AB154), mFOLFOX chemotherapy
Key Outcomes Measured Safety, tolerability, pharmacokinetics, objective response rate, progression-free survival, overall survival
Trial Phases Phase 1, Phase 1/1b, Phase 2
Notable Features Often studied in combination therapies, potential for enhancing immune response against cancer

FAQ

  • What is etrumadenant and how does it work? Etrumadenant (AB928) is an A2aR and A2bR antagonist. It works by blocking adenosine receptors, which play a role in suppressing the immune system. By inhibiting these receptors, etrumadenant may help boost the body's immune response against cancer cells.
  • What types of cancer is etrumadenant being studied for? Etrumadenant is being investigated for various cancer types, including non-small cell lung cancer, gastroesophageal cancer, colorectal cancer, prostate cancer, and urothelial carcinoma. It is often studied in combination with other cancer treatments.
  • How is etrumadenant administered to patients? Etrumadenant is typically administered orally as a daily dose. The exact dosage and schedule may vary depending on the specific clinical trial and combination therapy being studied.
  • What are some common combinations of drugs being tested with etrumadenant? Etrumadenant is often studied in combination with other cancer treatments. Common combinations include zimberelimab (an anti-PD-1 antibody), domvanalimab (an anti-TIGIT antibody), and standard chemotherapy regimens like mFOLFOX.
  • What are the potential side effects of etrumadenant? As with any drug in clinical trials, the full range of side effects is still being studied. Researchers are closely monitoring for adverse events and treatment-emergent side effects. The safety profile is being assessed in various trials to determine the drug's tolerability.

Ongoing Clinical Trials on Etrumadenant

  • Study on the Safety and Effectiveness of Etrumadenant, Quemliclustat, and Zimberelimab in Patients with Metastatic Colorectal Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • Etrumadenant (AB928): A drug that acts as an A2aR and A2bR antagonist, designed to boost the immune system's response against cancer cells by blocking adenosine receptors.
  • Zimberelimab (AB122): A fully human anti-PD-1 monoclonal antibody used in combination with etrumadenant in some clinical trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • mFOLFOX: A chemotherapy regimen that includes oxaliplatin, leucovorin, and 5-fluorouracil, often used in combination with etrumadenant in some trials.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.

References

  1. https://clinicaltrials.gov/study/NCT05277012
  2. https://clinicaltrials.gov/study/NCT05154136
  3. https://clinicaltrials.gov/study/NCT05335941
  4. https://clinicaltrials.gov/study/NCT04791839
  5. https://clinicaltrials.gov/study/NCT05177770
  6. https://clinicaltrials.gov/study/NCT03720678
  7. https://clinicaltrials.gov/study/NCT05886634
  8. https://clinicaltrials.gov/study/NCT05411146